Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Metformin in Metastatic Head and Neck Cancer
NCT04414540Phase 2Active, not recruiting
- Start
- Aug 2020
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs), pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Started Aug 2020; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04414540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414540.